CancerDrs

Lung Cancer clinical trials in California

121 actively recruiting lung cancer trials at 109 sites across California.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 3 Recruiting NIH

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in California:
  • Kaiser Permanente-Anaheim — Anaheim, California
  • Kaiser Permanente-Deer Valley Medical Center — Antioch, California
  • Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
  • PCR Oncology — Arroyo Grande, California
  • Sutter Auburn Faith Hospital — Auburn, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in California:
  • AIS Cancer Center at San Joaquin Community Hospital — Bakersfield, California
  • Mills-Peninsula Medical Center — Burlingame, California
  • Palo Alto Medical Foundation-Fremont — Fremont, California
  • Los Angeles General Medical Center — Los Angeles, California
  • USC / Norris Comprehensive Cancer Center — Los Angeles, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in California:
  • Providence - Saint Joseph Home Health - Anaheim — Anaheim, California
  • The Oncology Institute of Hope and Innovation - Corporate Office — Cerritos, California
  • Local Institution - 007-777 — Fountain Valley, California
  • Local Institution - 007-778 — Laguna Hills, California
  • Local Institution - 007-898-B — Long Beach, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…

Sponsor: Pfizer
NCT ID: NCT07222566
Sites in California:
  • Los Angeles Cancer Network - Anaheim — Anaheim, California
  • Los Angeles Cancer Network - Fountain Valley — Fountain Valley, California
  • Memorial Care Orange Coast Medical Center Attn — Fountain Valley, California
  • OC Blood and Cancer Care — Fountain Valley, California
  • Orange Coast Memorial Medical Center — Fountain Valley, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …

Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in California:
  • Cedars-Sinai Medical Center — Los Angeles, California
  • Mercy Cancer Center — Merced, California
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center — Torrance, California
  • BASS Cancer Center — Walnut Creek, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in California:
  • Clinical Study Site — Cerritos, California
  • Clinical Study Site — Glendale, California
  • Clinical Study Site — Irvine, California
  • Clinical Study Site — Los Angeles, California
  • Clinical Study Site — Mountain View, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…

Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in California:
  • UCLA Hematology/Oncology - Santa Monica — Los Angeles, California
  • Profound Research LLC — Oceanside, California
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center — Orange, California
  • Stanford Cancer Center — Palo Alto, California
  • Kaiser Permanente San Diego Mission Road — San Diego, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary en…

Sponsor: Summit Therapeutics
NCT ID: NCT05899608
Sites in California:
  • LA Cancer Network — Anaheim, California
  • The Oncology Institute of Hope & Innovation — Cerritos, California
  • University of Southern California (USC) — Los Angeles, California
  • Cedar Sinai Medical Center — Los Angeles, California
  • Valkyrie Clinical Trials — Los Angeles, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in California:
  • UC San Diego Health System - Encinitas — Encinitas, California
  • UC San Diego Moores Cancer Center — La Jolla, California
  • UC San Diego Medical Center - Hillcrest — San Diego, California
  • California Protons Cancer Therapy Center — San Diego, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in California:
  • Local Institution - 0581 — Fullerton, California
  • Local Institution - 0682 — Loma Linda, California
  • Helios Clinical Research — Long Beach, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in California:
  • Providence St. Jude Medical Center ( Site 0106) — Fullerton, California
  • VA Long Beach Healthcare System ( Site 0199) — Long Beach, California
  • USC Norris Comprehensive Cancer Center ( Site 0205) — Los Angeles, California
  • UCSF Medical Center at Mission Bay ( Site 0178) — San Francisco, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in California:
  • Local Institution - 0112 — Los Angeles, California
  • University of California Davis (UC Davis) Comprehensive Cancer Center — Sacramento, California
  • San Francisco Oncology Associates — San Francisco, California
  • UCLA Hematology/Oncology - Santa Monica — Santa Monica, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemot…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in California:
  • Local Institution - 0497 — Los Alamitos, California
  • USC/Norris Comprehensive Cancer Center — Los Angeles, California
  • Local Institution - 0444 — Los Angeles, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…

Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in California:
  • City of Hope (Adults and Pediatrics) — Duarte, California
  • University of California San Diego Moores Cancer Center (Adults only) — La Jolla, California
  • Loma Linda University Medical Center (Adults only) — Loma Linda, California
  • Children's Hospital Los Angeles, Div. of Research Immunology/BMT (Adults and Pediatrics) — Los Angeles, California
  • UCLA Medical Center (Adults and Pediatrics) — Los Angeles, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Sponsor: AstraZeneca
NCT ID: NCT06868277
Sites in California:
  • Research Site — La Mesa, California
  • Research Site — Los Alamitos, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).

Sponsor: AstraZeneca
NCT ID: NCT06417814
Sites in California:
  • Research Site — Duarte, California
  • Research Site — Fountain Valley, California
  • Research Site — La Jolla, California
  • Research Site — Los Angeles, California
  • Research Site — San Diego, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Long-term Extension Study of PCI-32765 (Ibrutinib)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in California:
  • City of Hope Cancer Center — Duarte, California
  • University of California San Diego Medical Center — La Jolla, California
  • University of California Los Angeles — Los Angeles, California
  • St. Joseph Hospital Center for Cancer Prevention and Treatment — Orange, California
  • Stanford University Medical Center — Stanford, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation thera…

Sponsor: Shanghai Junshi Bioscience Co., Ltd.
NCT ID: NCT06095583
Sites in California:
  • SCRI Nashville — Davis, California
  • Zangmeister Cancer Center (Columbus, OH) — Los Angeles, California
  • Los Angeles Hematology Oncology — Los Angeles, California
  • University of Southern California Norris Comprehensive Cancer — Los Angeles, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants …

Sponsor: ArriVent BioPharma, Inc.
NCT ID: NCT07185997
Sites in California:
  • USC/Norris Comprehensive Cancer Center — Los Angeles, California
  • University of California Davis Comprehensive Cancer Center — Sacramento, California
  • UCSF Medical Center-Mission Bay — San Francisco, California
  • Kaiser Permanente Medical Center — Vallejo, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in…

Sponsor: Nuvation Bio Inc.
NCT ID: NCT07154706
Sites in California:
  • UCLA — Los Angeles, California
  • UCI Chao Family Comprehensive Cancer Center — Orange, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging …

Sponsor: Vergent Bioscience, Inc.
NCT ID: NCT07499674
Sites in California:
  • City of Hope National Medical Center — Duarte, California
  • Hoag Memorial Hospital Presbyterian — Newport Beach, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

Arm 1 ( Phase 2/3 Run in ): PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with Carcinoma in Sit…

Sponsor: Privo Technologies
NCT ID: NCT05893888
Sites in California:
  • City of Hope National Medical Center — Duarte, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places i…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06031688
Sites in California:
  • Kaiser Permanente-Anaheim — Anaheim, California
  • Sutter Auburn Faith Hospital — Auburn, California
  • Kaiser Permanente-Baldwin Park — Baldwin Park, California
  • Kaiser Permanente-Bellflower — Bellflower, California
  • Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in California:
  • The Oncology Institute of Hope and Innovation — Cerritos, California
  • City of Hope Corona — Corona, California
  • City of Hope — Duarte, California
  • Providence Medical Foundation — Fullerton, California
  • Oncology Physicians Network Healthcare — Glendale, California
View on ClinicalTrials.gov →

Showing 25 of 121 trials with sites in California. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15